Eli Lilly (LLY): FY25 Q3 earnings call, Oct 30, 2025
No Kalshi or Polymarket word markets were listed for Eli Lilly’s Oct 30, 2025 earnings call (FY25 Q3). The transcript is searchable below (quotes of at most 25 words).
UpdatedTranscript
quotes of at most 25 wordsSpeaker-labelled transcript · Source and credits · Used to count words; quotes of at most 25 words.
13 matches for “Mounjaro”; 5 quoted, at least 25 words apart.
…of 10 prescriptions within this large and growing class. Outside the U.S. Mounjaro performance accelerated, driven by robust uptake around the world. As a result…
…increased 45% in Q3, driven by strong volume growth of Zepbound and Mounjaro partially offset by a 15% decline in price. Price was negatively impacted…
…increased by over 100% in constant currency, reflecting the strong uptake of Mounjaro. Revenue was positively impacted by $380 million onetime benefit related to a…
…this quarter and throughout 2026. Finally, moving to cardiometabolic health, Zepbound and Mounjaro both posted a strong global performance. Beginning outside the U.S. Mounjaro performance…
…limited internationally, we are encouraged by the strong uptake. Approximately 75% of Mounjaro revenue outside the U.S. is coming from people with obesity, paying out…
Agents: this page as TSV at /api/v1/appearances/eli-lilly:2025-10-30:earnings_call · words: /api/v1/brief?appearance=eli-lilly:2025-10-30:earnings_call · columnar JSON in #parrot-data · llms.txt · MCP